Steven J. Roy
Amministratore Delegato presso VetDC, Inc.
Profilo
Steven J.
Roy is currently the President, Chief Executive Officer & Director at VetDC, Inc. Prior to this, he worked as the Director-Licensing & Alliance Management at Amgen, Inc. from 1994 to 2007 and as a Laboratory Supervisor at Ligand Pharmaceuticals, Inc. from 1988 to 1992.
He received his undergraduate degree from the University of California San Diego and his MBA from the University of Michigan.
Posizioni attive di Steven J. Roy
Società | Posizione | Inizio |
---|---|---|
VetDC, Inc.
VetDC, Inc. Agricultural Commodities/MillingProcess Industries VetDC, Inc. develops cancer drugs for pets. It is a cancer-focused veterinary biopharmaceutical company developing innovative, underutilized human technologies for use in companion animals. It offers VDC-1101, a novel anti-cancer pro-drug from Gilead Sciences for use in animal cancer. The company was founded by Terry J. Opgenorth in 2009 and is headquartered in Fort Collins, CO. | Amministratore Delegato | 01/01/2010 |
Precedenti posizioni note di Steven J. Roy
Società | Posizione | Fine |
---|---|---|
AMGEN INC. | Corporate Officer/Principal | - |
LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Formazione di Steven J. Roy
University of California San Diego | Undergraduate Degree |
University of Michigan | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
AMGEN INC. | Health Technology |
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
Aziende private | 1 |
---|---|
VetDC, Inc.
VetDC, Inc. Agricultural Commodities/MillingProcess Industries VetDC, Inc. develops cancer drugs for pets. It is a cancer-focused veterinary biopharmaceutical company developing innovative, underutilized human technologies for use in companion animals. It offers VDC-1101, a novel anti-cancer pro-drug from Gilead Sciences for use in animal cancer. The company was founded by Terry J. Opgenorth in 2009 and is headquartered in Fort Collins, CO. | Process Industries |
- Borsa valori
- Insiders
- Steven J. Roy